List of Vitae Pharmaceuticals patents

Patents where

Current Assignee

Name

Vitae Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10047085 Dihydropyrrolopyridine inhibitors of ROR-gamma	Patent 10047085 was granted and assigned to Vitae Pharmaceuticals on August, 2018 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10047085	August 14, 2018
‌ US Patent 8383629 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1	Patent 8383629 was granted and assigned to Vitae Pharmaceuticals on February, 2013 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8383629	February 26, 2013
‌ US Patent 10336717 Inhibitors of beta-secretase	Patent 10336717 was granted and assigned to Vitae Pharmaceuticals on July, 2019 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10336717	July 2, 2019
‌ US Patent 11001583 Dihydropyrrolopyridine inhibitors of ROR-gamma	Patent 11001583 was granted and assigned to Vitae Pharmaceuticals on May, 2021 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	11001583	May 11, 2021
‌ US Patent 10899758 Inhibitors of the menin-MLL interaction	Patent 10899758 was granted and assigned to Vitae Pharmaceuticals on January, 2021 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10899758	January 26, 2021
‌ US Patent 7754737 Diaminoalkane aspartic protease inhibitors	Patent 7754737 was granted and assigned to Vitae Pharmaceuticals on July, 2010 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	7754737	July 13, 2010
‌ US Patent 8106221 Renin inhibitors	Patent 8106221 was granted and assigned to Vitae Pharmaceuticals on January, 2012 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8106221	January 31, 2012
‌ US Patent 10301261 Substituted indoles as modulators of ROR-gamma	Patent 10301261 was granted and assigned to Vitae Pharmaceuticals on May, 2019 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10301261	May 28, 2019
‌ US Patent 8455521 Diaminoalkane aspartic protease inhibitors	Patent 8455521 was granted and assigned to Vitae Pharmaceuticals on June, 2013 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8455521	June 4, 2013
‌ US Patent 9796710 Dihydropyrrolopyridine inhibitors of ROR-gamma	Patent 9796710 was granted and assigned to Vitae Pharmaceuticals on October, 2017 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9796710	October 24, 2017
‌ US Patent 9868748 Thiazolopyrrolidine inhibitors of ROR- γ	Patent 9868748 was granted and assigned to Vitae Pharmaceuticals on January, 2018 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9868748	January 16, 2018
‌ US Patent 7872028 Diaminopropanol renin inhibitors	Patent 7872028 was granted and assigned to Vitae Pharmaceuticals on January, 2011 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	7872028	January 18, 2011
‌ US Patent 9663515 Dihydropyrrolopyridine inhibitors of ROR-gamma	Patent 9663515 was granted and assigned to Vitae Pharmaceuticals on May, 2017 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9663515	May 30, 2017
‌ US Patent 8487108 Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors	Patent 8487108 was granted and assigned to Vitae Pharmaceuticals on July, 2013 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8487108	July 16, 2013
‌ US Patent 9045500 Inhibitors of beta-secretase	Patent 9045500 was granted and assigned to Vitae Pharmaceuticals on June, 2015 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9045500	June 2, 2015
‌ US Patent 9416135 Liver X receptor modulators	Patent 9416135 was granted and assigned to Vitae Pharmaceuticals on August, 2016 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9416135	August 16, 2016
‌ US Patent 10399976 Dihydropyrrolopyridine inhibitors of ROR-gamma	Patent 10399976 was granted and assigned to Vitae Pharmaceuticals on September, 2019 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10399976	September 3, 2019
‌ US Patent 9388190 Liver X receptor modulators	Patent 9388190 was granted and assigned to Vitae Pharmaceuticals on July, 2016 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9388190	July 12, 2016
‌ US Patent 9006244 Liver X receptor modulators	Patent 9006244 was granted and assigned to Vitae Pharmaceuticals on April, 2015 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	9006244	April 14, 2015
‌ US Patent 10144715 Piperazine derivatives as liver X receptor modulators	Patent 10144715 was granted and assigned to Vitae Pharmaceuticals on December, 2018 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10144715	December 4, 2018
‌ US Patent 8927715 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1	Patent 8927715 was granted and assigned to Vitae Pharmaceuticals on January, 2015 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8927715	January 6, 2015
‌ US Patent 8440658 Cyclic urea inhibitors of 11β-hydroxysteroid dehydrogenase 1	Patent 8440658 was granted and assigned to Vitae Pharmaceuticals on May, 2013 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8440658	May 14, 2013
‌ US Patent 10087184 Dihydropyrrolopyridine inhibitors of RORγ	Patent 10087184 was granted and assigned to Vitae Pharmaceuticals on October, 2018 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10087184	October 2, 2018
‌ US Patent 8084485 6-(aminoalkyl)indazoles	Patent 8084485 was granted and assigned to Vitae Pharmaceuticals on December, 2011 by the United States Patent and Trademark Office.		Vitae Pharmaceuticals	United States Patent and Trademark Office	8084485	December 27, 2011
‌ US Patent 10807980 Dihydropyrrolopyridine inhibitors of ROR-gamma	Patent 10807980 was granted and assigned to Vitae Pharmaceuticals on October, 2020 by the United States Patent and Trademark Office.	Vitae Pharmaceuticals	Vitae Pharmaceuticals	United States Patent and Trademark Office	10807980	October 20, 2020

Results per page:

61 results

0 selected

61 results

0 selected